When Bradford Hoppe, M.D., was in middle school, he was told to make a collage using magazine cutouts to visualize his future goals. He created an image of a doctor living near the beach.
Today, his artwork has become a reality. Dr. Hoppe serves as a consultant in the Department of Radiation Oncology at Mayo Clinic and lives with his family in Atlantic Beach, Florida. But it’s not just a childhood dream that drives him. After nearly losing both his wife and his father to cancer, he is more determined than ever to transform the future of cancer care.
Raised in Los Altos, California, Dr. Hoppe grew up admiring his father’s lifelong career as a radiation oncologist at Stanford Medicine.
Dr. Hoppe says his dad’s work in Hodgkin lymphoma left a lasting impression that made him eager to follow in his footsteps. While traditional radiation could cure the condition, it could also lead to serious long-term side effects such as second cancers or heart complications decades later.
“I became interested in this idea of optimizing clinical outcomes while minimizing risk of side effects. I knew I wanted to be part of the next generation of radiation therapy,” says Dr. Hoppe.
After earning a B.S. in biology at Stanford University and an M.D. at Cornell University Medical Center, Dr. Hoppe spent a year in Brazil conducting infectious disease and immunology research. He studied the impact of schistosomiasis, a parasitic disease, on the immune system and volunteered at a leprosy clinic.
“The work in infectious disease was really engaging in Brazil. But when I returned home, I knew I wanted to get back to my first passion: radiation oncology. I wanted to continue to advance the field just like my father had done.”
After spending most of his life on the West Coast, Dr. Hoppe moved to the East Coast to pursue a radiation oncology residency at Memorial Sloan Kettering Cancer Center in New York, where he met his future wife, Sonia.
After completing an M.P.H. at Harvard School of Public Health, the couple then moved to Florida where Sonia began working in radiation oncology at Mayo Clinic and Dr. Hoppe became a faculty member at the University of Florida Health Proton Therapy Institute. There, he held the James E. Lockwood Endowed Chair in Proton Therapy and pioneered the development of proton therapy in the management of lymphoma, thymoma and lung cancer before joining Mayo Clinic in 2019.
“My wife had been working at Mayo Clinic as a radiation therapist for about 10 years before I joined,” says Dr. Hoppe. “When Mayo Clinic announced its plans for particle therapy, I knew it was the right move.”
Dr. Hoppe is part of a team at Mayo Clinic that is bringing carbon ion radiation therapy to the United States. Similar to proton therapy, carbon ion can be delivered to a specific depth in the body, reducing damage to critical organs. However, unlike proton therapy, carbon ion causes clustered DNA damage, which is more effective in killing cancer cells, particularly with radiation-resistant cancers, and can be completed in less time than a traditional radiation therapy course.
Mayo Clinic’s Duan Family Building in Florida will provide advanced cancer treatment options that are currently only available in Asia and Europe. The building opened to patients in July 2025, with the first carbon ion treatment expected to be available by 2028.
We are building upon existing strategies and making them better to shape a new future. And we’re getting closer every day.
— Bradford Hoppe, M.D.
Dr. Hoppe and his colleagues have toured and learned from existing carbon ion centers in Japan, Germany, Taiwan, Korea, Italy and Austria. But it’s not a simple copy-and-paste process.
“Mayo Clinic is approaching carbon ion therapy differently than other institutions,” explains Dr. Hoppe. “Traditionally, carbon ion therapy has been limited to rare, hard-to-treat tumors that don’t respond well to other treatments. But with the advances in precision medicine, we are working to identify patients with radioresistant forms of more common cancers who could benefit.”
Dr. Hoppe is leading a collaborative clinical trial with centers in Europe and Asia to compare surgical treatment, proton radiation and carbon ion approaches for patients with pelvic bone sarcomas. The team is studying whether patients being treated with carbon ion therapy have higher cure rates compared with proton therapy and better functional quality of life compared with surgery.
Studies like this one will help experts better understand which cancers would benefit from carbon ion therapy.
“The key is knowing which patients will benefit from which treatments,” explains Dr. Hoppe. “It’s difficult for patients who have already undergone radiation unsuccessfully to jump into carbon ion because we don’t want to exceed radiation dose levels to critical structures and cause more problems for the patient. Our goal is to be able to identify the patients who would do better with carbon ion therapy at the time of diagnosis to improve outcomes and spare them from unnecessary side effects.”
While Dr. Hoppe has realized his childhood dream, his mission has grown even more meaningful.
“My wife and my father both were diagnosed with metastatic cancers more than five years ago that were expected to be terminal,” says Dr. Hoppe. “Both have undergone cutting-edge, personalized treatments and are in remission.”
Dr. Hoppe is building on his father’s legacy — but also creating his own. His research in bone sarcomas is just the beginning.
“I imagine a future where Mayo Clinic will be able to identify patients most suitable for proton therapy and carbon ion radiation therapy through radiomic and genomic signatures. That means better outcomes, fewer side effects and more lives saved. We are building upon existing strategies and making them better to shape a new future. And we’re getting closer every day.”
Integrated care environments are transforming how patients with complex conditions receive treatment.
Bold. Forward. Unbound. is a once-in-three-generations investment across Mayo Clinic.
This new equipment will allow Mayo Clinic to develop lifesaving cancer therapies.